Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand. It also provides Divina 3D surgical simulation systems to plastic surgeons for use in pre-surgical patient consultations and planning; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution. The company sells its products through exclusive distributors and direct sales force in Europe, Latin America, the Asia-Pacific, and internationally. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.
IPO Year: 2018
Exchange: NASDAQ
Website: establishmentlabs.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/20/2025 | $60.00 | Buy | Canaccord Genuity |
| 5/16/2025 | $62.00 | Buy | BTIG Research |
| 5/14/2025 | $48.00 | Hold → Buy | Needham |
| 4/14/2025 | Hold | Needham | |
| 5/22/2024 | $60.00 | Buy → Neutral | Citigroup |
| 8/31/2023 | $75.00 | Overweight | JP Morgan |
| 6/29/2023 | $79.00 | Buy | Citigroup |
| 10/14/2022 | $90.00 | Overweight | Stephens |
| 10/13/2022 | $70.00 | Buy | Mizuho |
| 8/24/2022 | $107.00 | Buy | B. Riley Securities |
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
4/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
4/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Canaccord Genuity initiated coverage of Establishment Labs with a rating of Buy and set a new price target of $60.00
BTIG Research initiated coverage of Establishment Labs with a rating of Buy and set a new price target of $62.00
Needham upgraded Establishment Labs from Hold to Buy and set a new price target of $48.00
Needham initiated coverage of Establishment Labs with a rating of Hold
Citigroup downgraded Establishment Labs from Buy to Neutral and set a new price target of $60.00
JP Morgan initiated coverage of Establishment Labs with a rating of Overweight and set a new price target of $75.00
Citigroup initiated coverage of Establishment Labs with a rating of Buy and set a new price target of $79.00
Stephens resumed coverage of Establishment Labs with a rating of Overweight and set a new price target of $90.00
Mizuho initiated coverage of Establishment Labs with a rating of Buy and set a new price target of $70.00
B. Riley Securities initiated coverage of Establishment Labs with a rating of Buy and set a new price target of $107.00
Fastest customizable press release news feed in the world
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended September 30, 2025, before the market opens on Wednesday, November 5, 2025, and will host a conference call at 8:30 am ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or +1 (201) 689-8037 (International) and use conference ID number 13750830. The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at ww
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, noted the publication of "The 3-Year Results of a 100-Patient Prospective Study of Safety and Effectiveness of Mia Femtech" in the Aesthetic Surgery Journal. The study showed a very low rate of complications, with no reports of capsular contracture (Baker Grade III/IV), implant rupture (including a 33-patient MRI cohort), nipple or breast sensitivity loss, incision-related complications, infection, seroma, rippling, hematoma, or BIA-ALCL; the reoperation rate at 3 years was 1%. Patient and surgeon satis
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced publication of its 2025 Post-Market Surveillance (PMS) Report. The report is being released ahead of the annual meeting of the American Society of Plastic Surgeons held October 9-12 in New Orleans. "Publishing our PMS report every year since the launch of Motiva in 2010 shows our dedication to accountability and transparency," said Peter Caldini, Establishment Labs Chief Executive Officer. "No other company in our industry publishes this level of information on an annual basis, and I would enc
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the second quarter ended June 30, 2025. Second Quarter Highlights and Outlook (Unaudited) Second quarter worldwide revenue of $51.3 million, an increase of 16.3% from the year ago period. Revenue included $10.3 million of Motiva sales in the United States. 2025 revenue guidance increased to $208 million to $212 million from $205 million to $210 million, year over year growth of 25%–28%, with at least $40 million in US Motiva revenue. Second quarter gross ma
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended June 30, 2025, before the market opens on Thursday, August 7, 2025, and will host a conference call at 8:30 am ET that day to discuss those results. To participate in the conference call, dial (416) 764 8646 (U.S. and Canada) or +1 (888) 396 8049 (International) and use conference ID number 13750829. The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at www.establ
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, will host its previously announced analyst and investor event in New York City on June 12, 2025 beginning at 1pm ET. A live and archived webcast of presentations and Q&A sessions on June 12 will be available on the "Investors" section of the Establishment Labs website at www.establishmentlabs.com. In-person attendance at the event is limited and requires advanced registration. Please email: [email protected] for further information. About Establishment Labs Establishment Labs Holdings Inc. is
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in the Jefferies Global Healthcare Conference. Peter Caldini, Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, are scheduled to present in a fireside chat on Wednesday, June 4, 2025 at 7:35 a.m. ET. A live webcast of the presentation will be available on the Establishment Labs investor relations website at https://investors.establishmentlabs.com/. Archived versions of the webcasts will be available on the same website following the completion of the e
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the first quarter ended March 31, 2025. First Quarter Highlights and Outlook First quarter worldwide revenue of $41.4 million, including $6.2 million of Motiva sales in the United States. 2025 revenue guidance maintained at $205 million to $210 million, year over year growth of 23%–26%. First quarter gross margin of 67.2% compared to 65.6% in the year-ago period. First quarter loss from operations was $16.9 million compared to a loss of $8.8 million in the ye
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced today the appointment of Peter Caldini as Chief Executive Officer effective May 7, 2025. Mr. Caldini has served as Interim CEO since March 1, 2025, when Establishment Labs' Founder and previous CEO Juan José Chacón-Quirós retired from the role. "After an extensive search process, it was clear that with his deep operational, commercial, and financial skills, Peter is the ideal person to lead Establishment Labs," commented Nick Lewin, Chairman of the Board of Establishment Labs. "We have a vision
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended March 31, 2025, after the market closes on Wednesday, May 7, 2025, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or +1 (201) 689-8037 (International) and use conference ID number 13750827. The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at www.establis
8-K - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)
SCHEDULE 13G/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)
10-Q - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)
8-K - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)
8-K - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)
8-K - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)
8-K - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)
DEFA14A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)
SCHEDULE 13G/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)
10-Q - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)
Live Leadership Updates
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced publication of its 2025 Post-Market Surveillance (PMS) Report. The report is being released ahead of the annual meeting of the American Society of Plastic Surgeons held October 9-12 in New Orleans. "Publishing our PMS report every year since the launch of Motiva in 2010 shows our dedication to accountability and transparency," said Peter Caldini, Establishment Labs Chief Executive Officer. "No other company in our industry publishes this level of information on an annual basis, and I would enc
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced today the appointment of Peter Caldini as Chief Executive Officer effective May 7, 2025. Mr. Caldini has served as Interim CEO since March 1, 2025, when Establishment Labs' Founder and previous CEO Juan José Chacón-Quirós retired from the role. "After an extensive search process, it was clear that with his deep operational, commercial, and financial skills, Peter is the ideal person to lead Establishment Labs," commented Nick Lewin, Chairman of the Board of Establishment Labs. "We have a vision
Peter Caldini to become Interim CEO effective March 1, 2025 Establishment Labs also announces preliminary unaudited fourth quarter revenue in line with recent guidance Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness in breast aesthetics and reconstruction, announced today that after twenty years as Chief Executive Officer (CEO), Juan José Chacón-Quirós has decided to retire as CEO, effective March 1, 2025. Peter Caldini, currently President of Establishment Labs, will serve as Interim CEO after that date. Mr. Chacón-Quirós will continue with Establishment Labs as both a board member and an active
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced today that Jeff Ehrhardt has joined the company as General Manager of North America. After having spent over 25 years at Allergan Aesthetics, an Abbvie Company, Mr. Ehrhardt joins Establishment Labs with responsibilities including the anticipated launch of Motiva implants in the U.S. later this year. "Jeff is the ideal person to introduce Motiva to the United States," said Juan José Chacón-Quirós, CEO and Founder of Establishment Labs. "Just as we have changed the standard for breast augmentat
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced the appointment of Raj Denhoy as Chief Financial Officer effective immediately. Mr. Denhoy has been with the company since February 2021, including as Interim Chief Financial Officer since August. "Raj has quickly become a trusted and vital colleague to me and many others at Establishment Labs," said Juan José Chacón-Quirós, Founder and CEO of Establishment Labs. "His depth of knowledge about our business and industry are matched by a clear vision of what we must do to achieve success as
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced the appointment of Leslie Gillin to its Board of Directors, effective immediately. "We are very pleased to welcome Leslie to the Board of Establishment Labs," said Juan José Chacón-Quirós, Founder and CEO of Establishment Labs. "She is extraordinarily accomplished in consumer marketing and finance, and her experience and insights will be invaluable as we continue to transform our industry by engaging directly with patients and by advancing new business and payment models." "I couldn't be
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, today announced the appointment of Ann Custin and Bryan Slotkin to its Board of Directors, effective immediately. "We are delighted to have these two very accomplished individuals join the Board of Establishment Labs," said Juan José Chacón-Quirós, Founder and CEO of Establishment Labs. "Good governance is essential to our mission of improving women's health. Their unique perspectives will be critical as we continue to reshape and expand our industry by offering differentiated technologies that create value for all stakeholder
Company also announces preliminary second quarter 2021 revenue of $31 million to $32 million Establishment Labs Holdings Inc. (NASDAQ:ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, today announced that Renee Gaeta will step down from her position as Chief Financial Officer for another opportunity outside of the company, effective July 30, 2021 and following the planned release of the company's second quarter financial results. Raj Denhoy, Head of Strategy and Investor Relations, has been named Interim Chief Financial Officer effective upon Mrs. Gaeta's departure. Establishment Labs also announced that prelimin
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, announced today that Pratip Dastidar has been appointed Head of Global Operations. Mr. Dastidar will join the executive team at Establishment Labs with responsibility for operational transformation and the scaling of global operations; he will also lead the company's digital transformation initiatives. Mr. Dastidar joins Establishment Labs from ServiceMaster, where he served as Chief Transformation Officer from 2018 to 2020. He previously was Head of Process Innovation at Salesforce and has held executive roles at Hewlett Pack
Live finance-specific insights
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended September 30, 2025, before the market opens on Wednesday, November 5, 2025, and will host a conference call at 8:30 am ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or +1 (201) 689-8037 (International) and use conference ID number 13750830. The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at ww
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the second quarter ended June 30, 2025. Second Quarter Highlights and Outlook (Unaudited) Second quarter worldwide revenue of $51.3 million, an increase of 16.3% from the year ago period. Revenue included $10.3 million of Motiva sales in the United States. 2025 revenue guidance increased to $208 million to $212 million from $205 million to $210 million, year over year growth of 25%–28%, with at least $40 million in US Motiva revenue. Second quarter gross ma
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended June 30, 2025, before the market opens on Thursday, August 7, 2025, and will host a conference call at 8:30 am ET that day to discuss those results. To participate in the conference call, dial (416) 764 8646 (U.S. and Canada) or +1 (888) 396 8049 (International) and use conference ID number 13750829. The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at www.establ
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the first quarter ended March 31, 2025. First Quarter Highlights and Outlook First quarter worldwide revenue of $41.4 million, including $6.2 million of Motiva sales in the United States. 2025 revenue guidance maintained at $205 million to $210 million, year over year growth of 23%–26%. First quarter gross margin of 67.2% compared to 65.6% in the year-ago period. First quarter loss from operations was $16.9 million compared to a loss of $8.8 million in the ye
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended March 31, 2025, after the market closes on Wednesday, May 7, 2025, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or +1 (201) 689-8037 (International) and use conference ID number 13750827. The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at www.establis
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the fourth quarter and full year ended December 31, 2024 and reaffirmed 2025 guidance. Fourth Quarter Highlights and Outlook Fourth quarter revenue of $44.5 million, consistent with preannouncement on January 13. Motiva Implants approved and launched in U.S.; Motiva U.S. revenue in the fourth quarter of $3.3 million. Fourth quarter net loss from operations of $18.7 million, a 15% reduction compared to a net loss of $22.1 million in the year-ago period. F
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended December 31, 2024, after the market closes on Wednesday, February 26, 2025, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or (201) 689-8037 (International) and use conference ID number 13750828. The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at www.e
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended September 30, 2024, after the market closes on Thursday, November 7, 2024, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or (201) 689-8037 (International) and use conference ID number 13749629. The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at www.est
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the second quarter ended June 30, 2024. Second Quarter Highlights and Outlook Second quarter worldwide revenue of $44.1 million. 2024 revenue guidance remains $174 million to $184 million, an increase of 5% to 11% over 2023. Gross profit for the second quarter was $28.9 million, or 65.6% of revenue, compared to $30.3 million, or 62.3% of revenue in the year-ago period. Second quarter loss from operations was $9.3 million compared to a loss of $13.7 milli
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended June 30, 2024, after the market closes on Tuesday, August 6, 2024, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (800) 715-9871 (U.S. and Canada) or (646) 307-1963 (International) and use conference ID number 7160745. The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at www.establishme
This live feed shows all institutional transactions in real time.
SC 13G - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)
SC 13G - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)
SC 13G/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)
SC 13G/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)
SC 13G - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)
SC 13G/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)
SC 13G/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)
SC 13G/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)
SC 13G/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)
SC 13G/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)